Vertex Completes NDA on CF Drug for G551D Mutation, Releases Data on Other Targeted CF Therapies
November 09, 2011
Vertex Completes NDA on CF Drug for G551D Mutation, Releases Data on Other Targeted CF Therapies
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Vertex Planning NDA Filing for CF Drug in Patients with G551D Mutations for Second Half of 2011
March 23, 2011 / Pharmacogenomics Reporter - GenomeWeb Feature: The Rise of Lung Cancer Genetic Testing
May 8, 2013 / Pharmacogenomics Reporter - MDx/CDx Focus: EC Approves Kalydeco; Cabozantinib in PGx-Targeted NSCLC; Ponatinib, CDx FDA Filing
August 1, 2012 / Pharmacogenomics Reporter - Vertex Says CF Patients with Double F508del Mutation Showing Improvement in VX-809/Kalydeco Trial
May 23, 2012 / Pharmacogenomics Reporter - Dual Study First to Suggest Genetic Basis for Personalized Adjunctive Tuberculosis Treatment
February 22, 2012 / Pharmacogenomics Reporter